SCHEMBL12778129

SCHEMBL12778129

N#Cc1ccc(F)cc1S(=O)(=O)N1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.56
▸ TSHR P16473 4/20 0.52
▸ HTR2A P28223 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ PKM P14618 2/20 0.49
▸ GPR183 P32249 1/20 0.46
▸ TDO2 P48775 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TRPV4 Q9HBA0 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12778084 0.98 KDM4E (0.58) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL12778097 0.98 KDM4E (0.58) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL14530321 0.87 TDO2 (0.58) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL12778115 0.82 NPC1 (0.71) KDM4EHTR2AHTR2CNPC1RAB9A
SCHEMBL12778088 0.80 HTR2A (0.49) HTR2AHTR2CPKMGPR183TDO2
SCHEMBL12778126 0.79 OTUD7B (0.43) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL12778134 0.78 HTR2A (0.43) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL12778138 0.78 HTR2A (0.43) KDM4ETSHRHTR2AHTR2CPKM
SCHEMBL4556004 0.78 PKM (0.71) KDM4ETSHRPKMCYP3A4CYP2C9
SCHEMBL1014809 0.78 PKM (0.67) KDM4ETSHRHTR2AHTR2CPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902182-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 — — US disclosed
US-7902182-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 — — US disclosed
WO-2007059229-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-24 — — WO disclosed
US-20070111985-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-05-17 — — US disclosed
US-20070111985-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111985-A1 HIV integrase inhibitors TYMP, POLN, IMPDH1 KDM4E 701/4885TSHR 4834/4885HTR2A 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback